Enanta Pharmaceuticals, Inc. (ENTA) 10-Year Financial Performance & Capital Metrics

ENTA • • Industrial / General

HealthcareBiotechnologyInfectious DiseasesHepatitis & Viral Infections

AboutEnanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.Show more

Revenue $65M -3.4%
EBITDA -$80M +32.8%
Net Income -$82M +29.4%
EPS (Diluted) -3.84 +29.9%
Gross Margin 100%
EBITDA Margin -122.86% +30.4%
Operating Margin -130.65% +27.4%
Net Margin -125.36% +26.9%
ROE -84.63% -26.0%
ROIC -23.23% +14.6%
Debt/Equity 3.11 +77.0%
Interest Coverage -11.11 +0.1%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 89 (top 11%)

✗Weaknesses

✗High debt to equity ratio of 3.1x
✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow
✗Sales declining 11.8% over 5 years
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-8.62%

5Y-11.81%

3Y-8.82%

TTM-9.94%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM20.22%

EPS CAGR

10Y-

5Y-

3Y-

TTM20.73%

ROCE

10Y Avg-11.41%

5Y Avg-31.87%

3Y Avg-33.8%

Latest-30.96%

Peer Comparison

Hepatitis & Viral Infections

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ADMAADMA Biologics, Inc.	4.16B	17.50	21.60	65.15%	42.87%	48.57%	2.64%	0.24
CVACCureVac N.V.	1.05B	4.66	6.47	8.96%	37.93%	33.02%	7.95%	0.06
DWTXDogwood Therapeutics, Inc.	83.24M	2.80	-0.22			-49.37%		0.24
ALGSAligos Therapeutics, Inc.	44.22M	8.26	-0.39	-74.6%	-32.68%	-120.37%
INOInovio Pharmaceuticals, Inc.	108.55M	1.58	-0.40	-73.83%	-592.82%	-115.42%		0.17
BRNSBarinthus Biotherapeutics plc	29.81M	0.73	-0.47	17.66%	-408%	-89.73%		0.09
COCPCocrystal Pharma, Inc.	15.3M	1.11	-0.65			-126.11%		0.19
KLRSKalaris Therapeutics Inc	165.7M	8.86	-0.76			-170.84%

Profit & Loss

	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Sales/Revenue+	88.27M	102.81M	206.63M	205.2M	122.47M	97.07M	86.16M	79.2M	67.64M	65.32M
Revenue Growth %	-0.45%	0.16%	1.01%	-0.01%	-0.4%	-0.21%	-0.11%	-0.08%	-0.15%	-0.03%
Cost of Goods Sold+	0	0	0	0	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	88.27M	102.81M	206.63M	205.2M	122.47M	97.07M	86.16M	79.2M	67.64M	65.32M
Gross Margin %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Gross Profit Growth %	-0.45%	0.16%	1.01%	-0.01%	-0.4%	-0.21%	-0.11%	-0.08%	-0.15%	-0.03%
Operating Expenses+	57.43M	78.2M	118.3M	168.46M	164.11M	206.65M	210M	216.41M	189.33M	150.67M
OpEx % of Revenue	0.65%	0.76%	0.57%	0.82%	1.34%	2.13%	2.44%	2.73%	2.8%	2.31%
Selling, General & Admin	16.97M	20.75M	23.44M	26.25M	27.36M	32.54M	45.48M	52.89M	57.85M	43.93M
SG&A % of Revenue	0.19%	0.2%	0.11%	0.13%	0.22%	0.34%	0.53%	0.67%	0.86%	0.67%
Research & Development	40.46M	57.45M	94.86M	142.21M	136.76M	174.11M	164.52M	163.52M	131.48M	106.74M
R&D % of Revenue	0.46%	0.56%	0.46%	0.69%	1.12%	1.79%	1.91%	2.06%	1.94%	1.63%
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	30.84M	24.61M	88.33M	36.74M	-41.64M	-109.57M	-123.84M	-137.21M	-121.69M	-85.35M
Operating Margin %	0.35%	0.24%	0.43%	0.18%	-0.34%	-1.13%	-1.44%	-1.73%	-1.8%	-1.31%
Operating Income Growth %	-0.75%	-0.2%	2.59%	-0.58%	-2.13%	-1.63%	-0.13%	-0.11%	0.11%	0.3%
EBITDA+	32.5M	26.75M	90.85M	40M	-37.99M	-106.24M	-120.87M	-134.84M	-119.36M	-80.26M
EBITDA Margin %	0.37%	0.26%	0.44%	0.19%	-0.31%	-1.09%	-1.4%	-1.7%	-1.76%	-1.23%
EBITDA Growth %	-0.74%	-0.18%	2.4%	-0.56%	-1.95%	-1.8%	-0.14%	-0.12%	0.11%	0.33%
D&A (Non-Cash Add-back)	1.66M	2.14M	2.52M	3.26M	3.64M	3.33M	2.97M	2.37M	2.34M	5.09M
EBIT	30.84M	24.61M	88.33M	36.74M	-41.64M	-107.58M	-122.19M	-125.85M	-106.85M	-75.87M
Net Interest Income+	1.69M	2.49M	4.85M	8.82M	6.47M	2.02M	1.57M	6.21M	3.83M	1.8M
Interest Income	1.74M	2.53M	0	8.82M	6.47M	2.02M	1.57M	11.36M	14.77M	9.48M
Interest Expense	45K	40K	4.85M	0	0	0	0	5.15M	10.94M	7.68M
Other Income/Expense	1.72M	2.33M	4.79M	8.82M	6.62M	1.99M	1.66M	6.21M	3.9M	1.8M
Pretax Income+	32.56M	26.95M	93.12M	45.56M	-35.02M	-107.58M	-122.19M	-131M	-117.79M	-83.55M
Pretax Margin %	0.37%	0.26%	0.45%	0.22%	-0.29%	-1.11%	-1.42%	-1.65%	-1.74%	-1.28%
Income Tax+	10.89M	9.24M	21.16M	-826K	1.15M	-28.58M	-433K	2.82M	-1.74M	-1.66M
Effective Tax Rate %	0.67%	0.66%	0.77%	1.02%	1.03%	0.73%	1%	1.02%	0.99%	0.98%
Net Income+	21.67M	17.71M	71.96M	46.38M	-36.17M	-79M	-121.75M	-133.82M	-116.05M	-81.89M
Net Margin %	0.25%	0.17%	0.35%	0.23%	-0.3%	-0.81%	-1.41%	-1.69%	-1.72%	-1.25%
Net Income Growth %	-0.73%	-0.18%	3.06%	-0.36%	-1.78%	-1.18%	-0.54%	-0.1%	0.13%	0.29%
Net Income (Continuing)	21.67M	17.71M	71.96M	46.38M	-36.17M	-79M	-121.75M	-133.82M	-116.05M	-81.89M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	1.13	0.91	3.48	2.21	-1.81	-3.92	-5.91	-6.38	-5.48	-3.84
EPS Growth %	-0.72%	-0.19%	2.82%	-0.36%	-1.82%	-1.17%	-0.51%	-0.08%	0.14%	0.3%
EPS (Basic)	1.14	0.93	3.48	2.37	-1.81	-3.92	-5.91	-6.38	-5.48	-3.84
Diluted Shares Outstanding	19.22M	19.41M	20.65M	20.97M	19.94M	20.17M	20.6M	20.97M	21.16M	21.34M
Basic Shares Outstanding	18.93M	19.07M	20.65M	19.58M	19.94M	20.17M	20.6M	20.97M	21.16M	21.34M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Total Current Assets+	232.16M	237.82M	380.39M	401.85M	436.84M	319.02M	311.71M	422.79M	299.85M	204.34M
Cash & Short-Term Investments	210.08M	223.67M	308.73M	335.24M	386.65M	244M	249.23M	369.91M	248.19M	188.86M
Cash Only	16.58M	65.67M	63.9M	51.23M	87.13M	57.21M	43.99M	85.39M	37.23M	32.3M
Short-Term Investments	193.51M	157.99M	244.83M	284.01M	299.52M	186.8M	205.24M	284.52M	210.95M	156.57M
Accounts Receivable	12.84M	10.61M	67.2M	51.31M	23.49M	60.83M	49.04M	39.62M	38.65M	6.88M
Days Sales Outstanding	53.1	37.68	118.72	91.27	70.01	228.73	207.73	182.57	208.55	38.45
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	9.23M	3.54M	4.45M	0	26.7M	14.19M	13.45M	0	608K	8.59M
Total Non-Current Assets+	49.12M	88.82M	33.84M	87.98M	53.95M	121.84M	68.88M	39.48M	76.8M	76.4M
Property, Plant & Equipment	8M	8.05M	8.37M	10.93M	15.62M	10.65M	29.75M	34.71M	73.35M	72.94M
Fixed Asset Turnover	11.03x	12.77x	24.67x	18.78x	7.84x	9.11x	2.90x	2.28x	0.92x	0.90x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	32.12M	70.04M	16.39M	65.01M	33.24M	109.02M	33.25M	3.97M	3.36M	3.36M
Other Non-Current Assets	608K	608K	700K	700K	92K	92K	696K	803K	94K	92K
Total Assets+	281.28M	326.64M	414.23M	489.83M	490.79M	440.86M	380.59M	462.27M	376.65M	280.73M
Asset Turnover	0.31x	0.31x	0.50x	0.42x	0.25x	0.22x	0.23x	0.17x	0.18x	0.23x
Asset Growth %	0.14%	0.16%	0.27%	0.18%	0%	-0.1%	-0.14%	0.21%	-0.19%	-0.25%
Total Current Liabilities+	7.89M	20.98M	16.02M	22.61M	24.16M	36.17M	29.83M	62.79M	57.53M	48.55M
Accounts Payable	3.38M	3.71M	4.75M	6.69M	5.74M	9.54M	6M	4.1M	8M	1.95M
Days Payables Outstanding	-	-	-	-	-	-	-	-	-	-
Short-Term Debt	0	0	0	0	4.26M	4.2M	2.89M	35.08M	34.46M	33.86M
Deferred Revenue (Current)	0	1000K	0	0	0	0	0	0	0	0
Other Current Liabilities	0	9.22M	0	0	9.38M	16.34M	14.5M	0	0	12.75M
Current Ratio	29.43x	11.33x	23.74x	17.77x	18.08x	8.82x	10.45x	6.73x	5.21x	4.21x
Quick Ratio	29.43x	11.33x	23.74x	17.77x	18.08x	8.82x	10.45x	6.73x	5.21x	4.21x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	3.45M	3.98M	4.52M	4.73M	11.05M	5.26M	29.43M	182.75M	190.3M	167.46M
Long-Term Debt	0	0	0	0	1.48M	1.51M	1.42M	160.85M	136.13M	112.44M
Capital Lease Obligations	458K	379K	293K	200K	3.84M	1.13M	22.37M	21.24M	53.94M	54.76M
Deferred Tax Liabilities	745K	1.18M	1.79M	1.75M	4.66M	2.07M	5.18M	0	0	0
Other Non-Current Liabilities	2.99M	3.6M	4.23M	4.53M	1.08M	558K	454K	663K	231K	260K
Total Liabilities	11.34M	24.96M	20.55M	27.34M	35.21M	41.43M	59.26M	245.54M	247.84M	216.01M
Total Debt+	531K	458K	293K	200K	9.58M	6.83M	26.69M	222.44M	226.06M	201.06M
Net Debt	-16.05M	-65.22M	-63.61M	-51.03M	-77.55M	-50.37M	-17.31M	137.05M	188.82M	168.76M
Debt / Equity	0.00x	0.00x	0.00x	0.00x	0.02x	0.02x	0.08x	1.03x	1.75x	3.11x
Debt / EBITDA	0.02x	0.02x	0.00x	0.01x	-	-	-	-	-	-
Net Debt / EBITDA	-0.49x	-2.44x	-0.70x	-1.28x	-	-	-	-	-	-
Interest Coverage	685.36x	615.35x	18.20x	-	-	-	-	-26.65x	-11.12x	-11.11x
Total Equity+	269.94M	301.68M	393.68M	462.49M	455.58M	399.43M	321.33M	216.74M	128.81M	64.72M
Equity Growth %	0.14%	0.12%	0.3%	0.17%	-0.01%	-0.12%	-0.2%	-0.33%	-0.41%	-0.5%
Book Value per Share	14.04	15.54	19.06	22.06	22.85	19.80	15.60	10.34	6.09	3.03
Total Shareholders' Equity	269.94M	301.68M	393.68M	462.49M	455.58M	399.43M	321.33M	216.74M	128.81M	64.72M
Common Stock	190K	191K	194K	197K	201K	202K	208K	211K	212K	214K
Retained Earnings	27.65M	45.36M	117.36M	163.74M	127.57M	48.58M	-73.18M	-207M	-323.04M	-404.93M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	19K	-112K	-398K	146K	844K	-382K	-3.72M	-1.17M	302K	-339K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Cash from Operations+	35.81M	52.65M	29.22M	71.42M	7.09M	-70M	-84.78M	-103.15M	-78.76M	-19.27M
Operating CF Margin %	0.41%	0.51%	0.14%	0.35%	0.06%	-0.72%	-0.98%	-1.3%	-1.16%	-0.3%
Operating CF Growth %	-0.53%	0.47%	-0.45%	1.44%	-0.9%	-10.88%	-0.21%	-0.22%	0.24%	0.76%
Net Income	21.67M	17.71M	71.96M	46.38M	-36.17M	-79M	-121.75M	-133.82M	-116.05M	-81.89M
Depreciation & Amortization	1.66M	2.14M	2.52M	3.26M	3.64M	3.33M	2.97M	2.37M	2.34M	5.09M
Stock-Based Compensation	9.35M	13.07M	15.85M	19.23M	19.57M	20.99M	26.97M	28.22M	26.8M	18.57M
Deferred Taxes	-2.29M	-1.65M	1.86M	-3.14M	10.61M	345K	0	0	0	0
Other Non-Cash Items	-749K	-581K	-1.17M	-5.8M	-3.47M	-1.98M	242K	-7.95M	1.02M	40.51M
Working Capital Changes	6.17M	21.97M	-61.79M	11.49M	12.9M	-13.69M	6.79M	8.02M	7.13M	-1.55M
Change in Receivables	2.45M	2.23M	-56.59M	15.89M	27.82M	-24.3M	11.79M	9.42M	973K	-236K
Change in Inventory	1.88M	18.63M	-6.42M	-6.48M	0	0	0	0	0	0
Change in Payables	1.45M	633K	1.32M	1.79M	-883K	3.77M	-4.63M	-1.15M	-414K	-1.31M
Cash from Investing+	-43.66M	-4.57M	-35.4M	-86.66M	19.83M	36.99M	54.9M	-53.58M	58.23M	40.35M
Capital Expenditures	-4.74M	-2.51M	-2.98M	-5.42M	-1.45M	-750K	-2.13M	-9.06M	-17.95M	-12.9M
CapEx % of Revenue	0.05%	0.02%	0.01%	0.03%	0.01%	0.01%	0.02%	0.11%	0.27%	0.2%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-38.92M	-2.07M	-32.42M	0	0	37.74M	54.9M	-44.52M	0	0
Cash from Financing+	2.71M	1.02M	4.41M	2.57M	8.98M	3.08M	20.03M	198.13M	-27.63M	-26.62M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	2.77M	1.09M	4.49M	2.66M	8.98M	3.08M	20.03M	198.13M	-147K	-26.62M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	31.07M	50.15M	26.24M	66M	5.64M	-70.75M	-86.91M	-112.21M	-96.71M	-32.17M
FCF Margin %	0.35%	0.49%	0.13%	0.32%	0.05%	-0.73%	-1.01%	-1.42%	-1.43%	-0.49%
FCF Growth %	-0.58%	0.61%	-0.48%	1.52%	-0.91%	-13.54%	-0.23%	-0.29%	0.14%	0.67%
FCF per Share	1.62	2.58	1.27	3.15	0.28	-3.51	-4.22	-5.35	-4.57	-1.51
FCF Conversion (FCF/Net Income)	1.65x	2.97x	0.41x	1.54x	-0.20x	0.89x	0.70x	0.77x	0.68x	0.24x
Interest Paid	0	0	0	0	0	0	0	1.99M	11.71M	0
Taxes Paid	12.62M	1.59M	26.09M	12.67M	105K	32K	0	4.9M	241K	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	8.56%	6.2%	20.7%	10.84%	-7.88%	-18.48%	-33.78%	-49.74%	-67.17%	-84.63%
Return on Invested Capital (ROIC)	9.87%	7.53%	23.39%	7.43%	-7.91%	-22.61%	-28.44%	-31.29%	-27.19%	-23.23%
Gross Margin	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%
Net Margin	24.55%	17.23%	34.82%	22.6%	-29.53%	-81.38%	-141.31%	-168.95%	-171.58%	-125.36%
Debt / Equity	0.00x	0.00x	0.00x	0.00x	0.02x	0.02x	0.08x	1.03x	1.75x	3.11x
Interest Coverage	685.36x	615.35x	18.20x	-	-	-	-	-26.65x	-11.12x	-11.11x
FCF Conversion	1.65x	2.97x	0.41x	1.54x	-0.20x	0.89x	0.70x	0.77x	0.68x	0.24x
Revenue Growth	-45.13%	16.48%	100.97%	-0.69%	-40.31%	-20.74%	-11.24%	-8.07%	-14.61%	-3.42%

Revenue by Segment

	2018	2019	2020	2021	2023	2024	2025
Royalty	191.63M	205.2M	122.47M	97.07M	78.2M	67.64M	65.32M
Royalty Growth	-	7.08%	-40.31%	-20.74%	-19.44%	-13.51%	-3.42%
License	-	-	-	-	1M	-	-
License Growth	-	-	-	-	-	-	-
Milestone	15M	-	-	-	-	-	-
Milestone Growth	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Enanta Pharmaceuticals, Inc. (ENTA) reported $64.8M in revenue for fiscal year 2025. This represents a 55% increase from $41.7M in 2012.

Enanta Pharmaceuticals, Inc. (ENTA) saw revenue decline by 3.4% over the past year.

Enanta Pharmaceuticals, Inc. (ENTA) reported a net loss of $92.0M for fiscal year 2025.

Dividend & Returns

Enanta Pharmaceuticals, Inc. (ENTA) has a return on equity (ROE) of -84.6%. Negative ROE indicates the company is unprofitable.

Enanta Pharmaceuticals, Inc. (ENTA) had negative free cash flow of $43.6M in fiscal year 2025, likely due to heavy capital investments.

US Stock Screener

...

Enanta Pharmaceuticals, Inc. (ENTA) 10-Year Financial Performance & Capital Metrics

ENTA • • Industrial / General

HealthcareBiotechnologyInfectious DiseasesHepatitis & Viral Infections

Revenue $65M -3.4%
EBITDA -$80M +32.8%
Net Income -$82M +29.4%
EPS (Diluted) -3.84 +29.9%
Gross Margin 100%
EBITDA Margin -122.86% +30.4%
Operating Margin -130.65% +27.4%
Net Margin -125.36% +26.9%
ROE -84.63% -26.0%
ROIC -23.23% +14.6%
Debt/Equity 3.11 +77.0%
Interest Coverage -11.11 +0.1%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 89 (top 11%)

✗Weaknesses

✗High debt to equity ratio of 3.1x
✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow
✗Sales declining 11.8% over 5 years
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-8.62%

5Y-11.81%

3Y-8.82%

TTM-9.94%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM20.22%

EPS CAGR

10Y-

5Y-

3Y-

TTM20.73%

ROCE

10Y Avg-11.41%

5Y Avg-31.87%

3Y Avg-33.8%

Latest-30.96%

Peer Comparison

Hepatitis & Viral Infections

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ADMAADMA Biologics, Inc.	4.16B	17.50	21.60	65.15%	42.87%	48.57%	2.64%	0.24
CVACCureVac N.V.	1.05B	4.66	6.47	8.96%	37.93%	33.02%	7.95%	0.06
DWTXDogwood Therapeutics, Inc.	83.24M	2.80	-0.22			-49.37%		0.24
ALGSAligos Therapeutics, Inc.	44.22M	8.26	-0.39	-74.6%	-32.68%	-120.37%
INOInovio Pharmaceuticals, Inc.	108.55M	1.58	-0.40	-73.83%	-592.82%	-115.42%		0.17
BRNSBarinthus Biotherapeutics plc	29.81M	0.73	-0.47	17.66%	-408%	-89.73%		0.09
COCPCocrystal Pharma, Inc.	15.3M	1.11	-0.65			-126.11%		0.19
KLRSKalaris Therapeutics Inc	165.7M	8.86	-0.76			-170.84%

Profit & Loss

	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Sales/Revenue+	88.27M	102.81M	206.63M	205.2M	122.47M	97.07M	86.16M	79.2M	67.64M	65.32M
Revenue Growth %	-0.45%	0.16%	1.01%	-0.01%	-0.4%	-0.21%	-0.11%	-0.08%	-0.15%	-0.03%
Cost of Goods Sold+	0	0	0	0	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	88.27M	102.81M	206.63M	205.2M	122.47M	97.07M	86.16M	79.2M	67.64M	65.32M
Gross Margin %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Gross Profit Growth %	-0.45%	0.16%	1.01%	-0.01%	-0.4%	-0.21%	-0.11%	-0.08%	-0.15%	-0.03%
Operating Expenses+	57.43M	78.2M	118.3M	168.46M	164.11M	206.65M	210M	216.41M	189.33M	150.67M
OpEx % of Revenue	0.65%	0.76%	0.57%	0.82%	1.34%	2.13%	2.44%	2.73%	2.8%	2.31%
Selling, General & Admin	16.97M	20.75M	23.44M	26.25M	27.36M	32.54M	45.48M	52.89M	57.85M	43.93M
SG&A % of Revenue	0.19%	0.2%	0.11%	0.13%	0.22%	0.34%	0.53%	0.67%	0.86%	0.67%
Research & Development	40.46M	57.45M	94.86M	142.21M	136.76M	174.11M	164.52M	163.52M	131.48M	106.74M
R&D % of Revenue	0.46%	0.56%	0.46%	0.69%	1.12%	1.79%	1.91%	2.06%	1.94%	1.63%
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	30.84M	24.61M	88.33M	36.74M	-41.64M	-109.57M	-123.84M	-137.21M	-121.69M	-85.35M
Operating Margin %	0.35%	0.24%	0.43%	0.18%	-0.34%	-1.13%	-1.44%	-1.73%	-1.8%	-1.31%
Operating Income Growth %	-0.75%	-0.2%	2.59%	-0.58%	-2.13%	-1.63%	-0.13%	-0.11%	0.11%	0.3%
EBITDA+	32.5M	26.75M	90.85M	40M	-37.99M	-106.24M	-120.87M	-134.84M	-119.36M	-80.26M
EBITDA Margin %	0.37%	0.26%	0.44%	0.19%	-0.31%	-1.09%	-1.4%	-1.7%	-1.76%	-1.23%
EBITDA Growth %	-0.74%	-0.18%	2.4%	-0.56%	-1.95%	-1.8%	-0.14%	-0.12%	0.11%	0.33%
D&A (Non-Cash Add-back)	1.66M	2.14M	2.52M	3.26M	3.64M	3.33M	2.97M	2.37M	2.34M	5.09M
EBIT	30.84M	24.61M	88.33M	36.74M	-41.64M	-107.58M	-122.19M	-125.85M	-106.85M	-75.87M
Net Interest Income+	1.69M	2.49M	4.85M	8.82M	6.47M	2.02M	1.57M	6.21M	3.83M	1.8M
Interest Income	1.74M	2.53M	0	8.82M	6.47M	2.02M	1.57M	11.36M	14.77M	9.48M
Interest Expense	45K	40K	4.85M	0	0	0	0	5.15M	10.94M	7.68M
Other Income/Expense	1.72M	2.33M	4.79M	8.82M	6.62M	1.99M	1.66M	6.21M	3.9M	1.8M
Pretax Income+	32.56M	26.95M	93.12M	45.56M	-35.02M	-107.58M	-122.19M	-131M	-117.79M	-83.55M
Pretax Margin %	0.37%	0.26%	0.45%	0.22%	-0.29%	-1.11%	-1.42%	-1.65%	-1.74%	-1.28%
Income Tax+	10.89M	9.24M	21.16M	-826K	1.15M	-28.58M	-433K	2.82M	-1.74M	-1.66M
Effective Tax Rate %	0.67%	0.66%	0.77%	1.02%	1.03%	0.73%	1%	1.02%	0.99%	0.98%
Net Income+	21.67M	17.71M	71.96M	46.38M	-36.17M	-79M	-121.75M	-133.82M	-116.05M	-81.89M
Net Margin %	0.25%	0.17%	0.35%	0.23%	-0.3%	-0.81%	-1.41%	-1.69%	-1.72%	-1.25%
Net Income Growth %	-0.73%	-0.18%	3.06%	-0.36%	-1.78%	-1.18%	-0.54%	-0.1%	0.13%	0.29%
Net Income (Continuing)	21.67M	17.71M	71.96M	46.38M	-36.17M	-79M	-121.75M	-133.82M	-116.05M	-81.89M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	1.13	0.91	3.48	2.21	-1.81	-3.92	-5.91	-6.38	-5.48	-3.84
EPS Growth %	-0.72%	-0.19%	2.82%	-0.36%	-1.82%	-1.17%	-0.51%	-0.08%	0.14%	0.3%
EPS (Basic)	1.14	0.93	3.48	2.37	-1.81	-3.92	-5.91	-6.38	-5.48	-3.84
Diluted Shares Outstanding	19.22M	19.41M	20.65M	20.97M	19.94M	20.17M	20.6M	20.97M	21.16M	21.34M
Basic Shares Outstanding	18.93M	19.07M	20.65M	19.58M	19.94M	20.17M	20.6M	20.97M	21.16M	21.34M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Total Current Assets+	232.16M	237.82M	380.39M	401.85M	436.84M	319.02M	311.71M	422.79M	299.85M	204.34M
Cash & Short-Term Investments	210.08M	223.67M	308.73M	335.24M	386.65M	244M	249.23M	369.91M	248.19M	188.86M
Cash Only	16.58M	65.67M	63.9M	51.23M	87.13M	57.21M	43.99M	85.39M	37.23M	32.3M
Short-Term Investments	193.51M	157.99M	244.83M	284.01M	299.52M	186.8M	205.24M	284.52M	210.95M	156.57M
Accounts Receivable	12.84M	10.61M	67.2M	51.31M	23.49M	60.83M	49.04M	39.62M	38.65M	6.88M
Days Sales Outstanding	53.1	37.68	118.72	91.27	70.01	228.73	207.73	182.57	208.55	38.45
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	9.23M	3.54M	4.45M	0	26.7M	14.19M	13.45M	0	608K	8.59M
Total Non-Current Assets+	49.12M	88.82M	33.84M	87.98M	53.95M	121.84M	68.88M	39.48M	76.8M	76.4M
Property, Plant & Equipment	8M	8.05M	8.37M	10.93M	15.62M	10.65M	29.75M	34.71M	73.35M	72.94M
Fixed Asset Turnover	11.03x	12.77x	24.67x	18.78x	7.84x	9.11x	2.90x	2.28x	0.92x	0.90x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	32.12M	70.04M	16.39M	65.01M	33.24M	109.02M	33.25M	3.97M	3.36M	3.36M
Other Non-Current Assets	608K	608K	700K	700K	92K	92K	696K	803K	94K	92K
Total Assets+	281.28M	326.64M	414.23M	489.83M	490.79M	440.86M	380.59M	462.27M	376.65M	280.73M
Asset Turnover	0.31x	0.31x	0.50x	0.42x	0.25x	0.22x	0.23x	0.17x	0.18x	0.23x
Asset Growth %	0.14%	0.16%	0.27%	0.18%	0%	-0.1%	-0.14%	0.21%	-0.19%	-0.25%
Total Current Liabilities+	7.89M	20.98M	16.02M	22.61M	24.16M	36.17M	29.83M	62.79M	57.53M	48.55M
Accounts Payable	3.38M	3.71M	4.75M	6.69M	5.74M	9.54M	6M	4.1M	8M	1.95M
Days Payables Outstanding	-	-	-	-	-	-	-	-	-	-
Short-Term Debt	0	0	0	0	4.26M	4.2M	2.89M	35.08M	34.46M	33.86M
Deferred Revenue (Current)	0	1000K	0	0	0	0	0	0	0	0
Other Current Liabilities	0	9.22M	0	0	9.38M	16.34M	14.5M	0	0	12.75M
Current Ratio	29.43x	11.33x	23.74x	17.77x	18.08x	8.82x	10.45x	6.73x	5.21x	4.21x
Quick Ratio	29.43x	11.33x	23.74x	17.77x	18.08x	8.82x	10.45x	6.73x	5.21x	4.21x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	3.45M	3.98M	4.52M	4.73M	11.05M	5.26M	29.43M	182.75M	190.3M	167.46M
Long-Term Debt	0	0	0	0	1.48M	1.51M	1.42M	160.85M	136.13M	112.44M
Capital Lease Obligations	458K	379K	293K	200K	3.84M	1.13M	22.37M	21.24M	53.94M	54.76M
Deferred Tax Liabilities	745K	1.18M	1.79M	1.75M	4.66M	2.07M	5.18M	0	0	0
Other Non-Current Liabilities	2.99M	3.6M	4.23M	4.53M	1.08M	558K	454K	663K	231K	260K
Total Liabilities	11.34M	24.96M	20.55M	27.34M	35.21M	41.43M	59.26M	245.54M	247.84M	216.01M
Total Debt+	531K	458K	293K	200K	9.58M	6.83M	26.69M	222.44M	226.06M	201.06M
Net Debt	-16.05M	-65.22M	-63.61M	-51.03M	-77.55M	-50.37M	-17.31M	137.05M	188.82M	168.76M
Debt / Equity	0.00x	0.00x	0.00x	0.00x	0.02x	0.02x	0.08x	1.03x	1.75x	3.11x
Debt / EBITDA	0.02x	0.02x	0.00x	0.01x	-	-	-	-	-	-
Net Debt / EBITDA	-0.49x	-2.44x	-0.70x	-1.28x	-	-	-	-	-	-
Interest Coverage	685.36x	615.35x	18.20x	-	-	-	-	-26.65x	-11.12x	-11.11x
Total Equity+	269.94M	301.68M	393.68M	462.49M	455.58M	399.43M	321.33M	216.74M	128.81M	64.72M
Equity Growth %	0.14%	0.12%	0.3%	0.17%	-0.01%	-0.12%	-0.2%	-0.33%	-0.41%	-0.5%
Book Value per Share	14.04	15.54	19.06	22.06	22.85	19.80	15.60	10.34	6.09	3.03
Total Shareholders' Equity	269.94M	301.68M	393.68M	462.49M	455.58M	399.43M	321.33M	216.74M	128.81M	64.72M
Common Stock	190K	191K	194K	197K	201K	202K	208K	211K	212K	214K
Retained Earnings	27.65M	45.36M	117.36M	163.74M	127.57M	48.58M	-73.18M	-207M	-323.04M	-404.93M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	19K	-112K	-398K	146K	844K	-382K	-3.72M	-1.17M	302K	-339K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Cash from Operations+	35.81M	52.65M	29.22M	71.42M	7.09M	-70M	-84.78M	-103.15M	-78.76M	-19.27M
Operating CF Margin %	0.41%	0.51%	0.14%	0.35%	0.06%	-0.72%	-0.98%	-1.3%	-1.16%	-0.3%
Operating CF Growth %	-0.53%	0.47%	-0.45%	1.44%	-0.9%	-10.88%	-0.21%	-0.22%	0.24%	0.76%
Net Income	21.67M	17.71M	71.96M	46.38M	-36.17M	-79M	-121.75M	-133.82M	-116.05M	-81.89M
Depreciation & Amortization	1.66M	2.14M	2.52M	3.26M	3.64M	3.33M	2.97M	2.37M	2.34M	5.09M
Stock-Based Compensation	9.35M	13.07M	15.85M	19.23M	19.57M	20.99M	26.97M	28.22M	26.8M	18.57M
Deferred Taxes	-2.29M	-1.65M	1.86M	-3.14M	10.61M	345K	0	0	0	0
Other Non-Cash Items	-749K	-581K	-1.17M	-5.8M	-3.47M	-1.98M	242K	-7.95M	1.02M	40.51M
Working Capital Changes	6.17M	21.97M	-61.79M	11.49M	12.9M	-13.69M	6.79M	8.02M	7.13M	-1.55M
Change in Receivables	2.45M	2.23M	-56.59M	15.89M	27.82M	-24.3M	11.79M	9.42M	973K	-236K
Change in Inventory	1.88M	18.63M	-6.42M	-6.48M	0	0	0	0	0	0
Change in Payables	1.45M	633K	1.32M	1.79M	-883K	3.77M	-4.63M	-1.15M	-414K	-1.31M
Cash from Investing+	-43.66M	-4.57M	-35.4M	-86.66M	19.83M	36.99M	54.9M	-53.58M	58.23M	40.35M
Capital Expenditures	-4.74M	-2.51M	-2.98M	-5.42M	-1.45M	-750K	-2.13M	-9.06M	-17.95M	-12.9M
CapEx % of Revenue	0.05%	0.02%	0.01%	0.03%	0.01%	0.01%	0.02%	0.11%	0.27%	0.2%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-38.92M	-2.07M	-32.42M	0	0	37.74M	54.9M	-44.52M	0	0
Cash from Financing+	2.71M	1.02M	4.41M	2.57M	8.98M	3.08M	20.03M	198.13M	-27.63M	-26.62M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	2.77M	1.09M	4.49M	2.66M	8.98M	3.08M	20.03M	198.13M	-147K	-26.62M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	31.07M	50.15M	26.24M	66M	5.64M	-70.75M	-86.91M	-112.21M	-96.71M	-32.17M
FCF Margin %	0.35%	0.49%	0.13%	0.32%	0.05%	-0.73%	-1.01%	-1.42%	-1.43%	-0.49%
FCF Growth %	-0.58%	0.61%	-0.48%	1.52%	-0.91%	-13.54%	-0.23%	-0.29%	0.14%	0.67%
FCF per Share	1.62	2.58	1.27	3.15	0.28	-3.51	-4.22	-5.35	-4.57	-1.51
FCF Conversion (FCF/Net Income)	1.65x	2.97x	0.41x	1.54x	-0.20x	0.89x	0.70x	0.77x	0.68x	0.24x
Interest Paid	0	0	0	0	0	0	0	1.99M	11.71M	0
Taxes Paid	12.62M	1.59M	26.09M	12.67M	105K	32K	0	4.9M	241K	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	8.56%	6.2%	20.7%	10.84%	-7.88%	-18.48%	-33.78%	-49.74%	-67.17%	-84.63%
Return on Invested Capital (ROIC)	9.87%	7.53%	23.39%	7.43%	-7.91%	-22.61%	-28.44%	-31.29%	-27.19%	-23.23%
Gross Margin	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%
Net Margin	24.55%	17.23%	34.82%	22.6%	-29.53%	-81.38%	-141.31%	-168.95%	-171.58%	-125.36%
Debt / Equity	0.00x	0.00x	0.00x	0.00x	0.02x	0.02x	0.08x	1.03x	1.75x	3.11x
Interest Coverage	685.36x	615.35x	18.20x	-	-	-	-	-26.65x	-11.12x	-11.11x
FCF Conversion	1.65x	2.97x	0.41x	1.54x	-0.20x	0.89x	0.70x	0.77x	0.68x	0.24x
Revenue Growth	-45.13%	16.48%	100.97%	-0.69%	-40.31%	-20.74%	-11.24%	-8.07%	-14.61%	-3.42%

Revenue by Segment

	2018	2019	2020	2021	2023	2024	2025
Royalty	191.63M	205.2M	122.47M	97.07M	78.2M	67.64M	65.32M
Royalty Growth	-	7.08%	-40.31%	-20.74%	-19.44%	-13.51%	-3.42%
License	-	-	-	-	1M	-	-
License Growth	-	-	-	-	-	-	-
Milestone	15M	-	-	-	-	-	-
Milestone Growth	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Enanta Pharmaceuticals, Inc. (ENTA) reported $64.8M in revenue for fiscal year 2025. This represents a 55% increase from $41.7M in 2012.

Enanta Pharmaceuticals, Inc. (ENTA) saw revenue decline by 3.4% over the past year.

Enanta Pharmaceuticals, Inc. (ENTA) reported a net loss of $92.0M for fiscal year 2025.

Dividend & Returns

Enanta Pharmaceuticals, Inc. (ENTA) has a return on equity (ROE) of -84.6%. Negative ROE indicates the company is unprofitable.

Enanta Pharmaceuticals, Inc. (ENTA) had negative free cash flow of $43.6M in fiscal year 2025, likely due to heavy capital investments.